bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental figure 3 from Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy
Authors: Santana-Magal Nadine , Farhat-Younis Leen , Gutwillig Amit , Gleiberman Annette , Rasoulouniriana Diana , Tal Lior , Netanely Dvir , Shamir Ron , Blau Rachel , Feinmesser Meora , Zlotnik Oran , Gutman Haim , Linde Ian L. , Reticker-Flynn Nathan E. , Rider Peleg , Carmi Yaron
Published: April 2023

Tumor antigens are drained into sentinel lymph nodes independently of dendritic cell migration.
Supplementary Figure S5 from Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R–MEK5–Erk5 Pathway
Authors: Benito-Jardón Lucía , Díaz-Martínez Marta , Arellano-Sánchez Nohemi , Vaquero-Morales Paloma , Esparís-Ogando Azucena , Teixidó Joaquin
Published: April 2023

Growth factor arrays and TGF-alpha effect on cell growth
Supplemental Figure 1 from Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy
Authors: Santana-Magal Nadine , Farhat-Younis Leen , Gutwillig Amit , Gleiberman Annette , Rasoulouniriana Diana , Tal Lior , Netanely Dvir , Shamir Ron , Blau Rachel , Feinmesser Meora , Zlotnik Oran , Gutman Haim , Linde Ian L. , Reticker-Flynn Nathan E. , Rider Peleg , Carmi Yaron
Published: April 2023

Higher doses of immunmotherapy do not induce tumor regression when administrated to large melanoma lesions.
Supplementary Figure 2 from Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan–Targeting Antibodies without the Need for Immune Effector Cells or Complement
Authors: Vankemmelbeke Mireille , McIntosh Richard S. , Chua Jia Xin , Kirk Thomas , Daniels Ian , Patsalidou Marilena , Moss Robert , Parsons Tina , Scott David , Harris Gemma , Ramage Judith M. , Spendlove Ian , Durrant Lindy G.
Published: April 2023

IEDB screen for MHC class II binding epitopes
Supplementary Data from Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM+ Hepatocellular Carcinoma
Authors: Takai Atsushi , Dang Hien , Oishi Naoki , Khatib Subreen , Martin Sean P. , Dominguez Dana A. , Luo Ji , Bagni Rachel , Wu Xiaolin , Powell Katie , Ye Qing-Hai , Jia Hu-Liang , Qin Lun-Xiu , Chen Jinqiu , Mitchell Gary A. , Luo Xiaoling , Thorgeirsson Snorri S. , Wang Xin Wei
Published: April 2023

Supplementary Tables from RNAi screening analyses.
Supplementary Data from Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM+ Hepatocellular Carcinoma
Authors: Takai Atsushi , Dang Hien , Oishi Naoki , Khatib Subreen , Martin Sean P. , Dominguez Dana A. , Luo Ji , Bagni Rachel , Wu Xiaolin , Powell Katie , Ye Qing-Hai , Jia Hu-Liang , Qin Lun-Xiu , Chen Jinqiu , Mitchell Gary A. , Luo Xiaoling , Thorgeirsson Snorri S. , Wang Xin Wei
Published: April 2023

Supplementary figures as related to the manuscript. Data represent schematic RNAi screen workflow, additional survival analyses, and experiments performed in different hepatocellular carcinoma cell lines.
Supplementary Table S1 from NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma
Authors: Valencia-Sama Ivette , Ladumor Yagnesh , Kee Lynn , Adderley Teresa , Christopher Gabriella , Robinson Claire M. , Kano Yoshihito , Ohh Michael , Irwin Meredith S.
Published: April 2023

Table S1 - Genetic background of neuroblastoma cell lines.
Supplementary Figures S1-S10 from NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma
Authors: Valencia-Sama Ivette , Ladumor Yagnesh , Kee Lynn , Adderley Teresa , Christopher Gabriella , Robinson Claire M. , Kano Yoshihito , Ohh Michael , Irwin Meredith S.
Published: April 2023

Figure S1 - Sensitivity of NB cell lines to allosteric SHP2 inhibitors. Figure S2 - Sensitivity of NB cell lines to catalytic SHP2 inhibitors. Figure S3 - Sensitivity to SHP2 inhibitors in isogenic NB cells with exogenous PTPN11 mutations. Figure S4 - NRAS status determines sensitivity to SHP2 and MAPK inhibition. Figure S5 - MAPK inhibitors sensitize NB cells to SHP099 and II-B08. Figure S6 - SHP2 inhibitors are synergistic with trametinib and other MAPK inhibitors. Figure S7 - MAPK inhibitors synergize with SHP2 inhibitors in ALK-mutant NB cells. Figure S8 - Assessment of drug tolerability for SHP099 and trametinib in vivo. Figure S9 - Pre-clinical assessment of SHP099 plus trametinib in NRAS-mutant NB xenografts. Figure S10 - Pre-clinical assessment of SHP099 plus ulixertinib in NRAS-mutant NB xenografts.
Supplementary Table 1 from ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer
Authors: Rafiei Shahrzad , Fitzpatrick Kenyon , Liu David , Cai Mu-Yan , Elmarakeby Haitham A. , Park Jihye , Ricker Cora , Kochupurakkal Bose S. , Choudhury Atish D. , Hahn William C. , Balk Steven P. , Hwang Justin H. , Van Allen Eliezer M. , Mouw Kent W.
Published: April 2023

siRNA and sgRNA sequences
Figure S6 from p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis
Authors: Wang Fang , Qi Xiao-Mei , Wertz Ryan , Mortensen Matthew , Hagen Catherine , Evans John , Sheinin Yuri , James Michael , Liu Pengyuan , Tsai Susan , Thomas James , Mackinnon Alexander , Dwinell Michael , Myers Charles R. , Bartrons Bach Ramon , Fu Liwu , Chen Guan
Published: April 2023

Figure S6. PFD inhibits xenograft-growth of human Pdac, decreases Ki67, p-PFKFB3 and PFKFB3 protein levels in tumor tissues, and cooperates with PFK15 to inhibit glucose uptake, lactate secretion and colony formation in KPC, but not in KPC/p38ÃƒÅ½Ã,Â³ KO, cells.
Figure S5 from p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis
Authors: Wang Fang , Qi Xiao-Mei , Wertz Ryan , Mortensen Matthew , Hagen Catherine , Evans John , Sheinin Yuri , James Michael , Liu Pengyuan , Tsai Susan , Thomas James , Mackinnon Alexander , Dwinell Michael , Myers Charles R. , Bartrons Bach Ramon , Fu Liwu , Chen Guan
Published: April 2023

Figure S5. PFD decreases p-PFKFB3, PFKFB3 and Glut2 expression in primary KPC tumors and suppresses allograft growth of KPC, but not KPC/p38ÃƒÅ½Ã,Â³ KO tumor, in association with decreased Ki67, p-PFKFB3, PFKFB3 and ÃƒÅ½Ã,Â±-SMA expression in tumor tissues.
Supplementary Figure 3 from Hispanic/Latino Patients with Gastric Adenocarcinoma Have Distinct Molecular Profiles Including a High Rate of Germline CDH1 Variants
Authors: Wang Sam C. , Yeu Yunku , Hammer Suntrea T.G. , Xiao Shu , Zhu Min , Hong Changjin , Clemenceau Jean R. , Yoon Lynn Y. , Nassour Ibrahim , Shen Jeanne , Agarwal Deepak , Reznik Scott I. , Mansour John C. , Yopp Adam C. , Zhu Hao , Hwang Tae Hyun , Porembka Matthew R.
Published: April 2023

Subgroup analysis of overall survival for the Hispanic/Latino cohort. Kaplan-Meier curves comparing: a. all patients by individual mRNA clusters, P < 0.01, b. patients with genomically stable tumors, P < 0.05, c. patients with chromosomal instable tumors, P < 0.05, d. patients with diffuse-type tumors, P < 0.05, e. patients with intestinal-type tumors, P < 0.05.
Supplementary Data from Therapeutic Potential of the miRNA–ATM Axis in the Management of Tumor Radioresistance
Authors: Rezaeian Abdol-Hossein , Khanbabaei Hashem , Calin George A.
Published: April 2023

S Fig 1
Supplementary Figures 1-12 from CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells
Authors: Rogers Rebecca F. , Walton Michael I. , Cherry Daniel L. , Collins Ian , Clarke Paul A. , Garrett Michelle D. , Workman Paul
Published: April 2023

Supplementary Figures - SF1: GI50 determinations for CHK1 inhibitor SRA737 in A549 and SW620 cells. SF2: Knockdown of POLA1, POLE or POLE2 sensitises A549 and SW620 cells to the CHK1 inhibitor MK-8776. SF3: Knockdown of CHK1 sensitises A549 cells to the DNA polymerase inhibitor aphidicolin. SF4: POLA1, POLE or POLE2 knockdown is synthetically lethal with the CHK1 inhibitor SRA737 in additional NSCLC and colorectal cancer cell lines. SF5: Western blot analysis of POLA1, POLE and POLE2 knockdown in additional NSCLC cell lines. Western blot analysis of POLA1, POLE and POLE2 knockdown in additional colorectal cancer cell lines. SF7: SRA737 and gemcitabine synergistically inhibit the proliferation of 4 NSCLC cell lines. SF8: An additive interaction between SRA737 and aphidicolin in the HBEC3-KT cell line. SF9: Effect of CHK1 or B-family DNA polymerase pharmacological inhibition alone or in combination on RPA32 phosphorylation in A549 cells. SF10: Effect of CHK1 or B-family DNA polymerase pharmacological inhibition alone or in combination on ï�§H2AX foci in A549 cells. SF 11: Correlation between POLA1, POLE and POLE2 basal protein expression in NSCLC and colorectal cancer cell lines. SF12: Lack of correlation between POLA, POLE and POLE2 basal protein expression and SRA737 or aphidicolin combination indices in NSCLC and colorectal cancer cell lines.
Supplementary Data File S4 from Metastatic Conditioning of Myeloid Cells at a Subcutaneous Synthetic Niche Reflects Disease Progression and Predicts Therapeutic Outcomes
Authors: Oakes Robert S. , Bushnell Grace G. , Orbach Sophia M. , Kandagatla Pridvi , Zhang Yining , Morris Aaron H. , Hall Matthew S. , LaFaire Petrina , Decker Joseph T. , Hartfield Rachel M. , Brooks Michael D. , Wicha Max S. , Jeruss Jacqueline S. , Shea Lonnie D.
Published: April 2023

Workbook organized into spreadsheets detailing statistical findings for the manuscript including all exact F and p values. Syntax for SPSS analysis is listed at the top of each sheet for subsequent statistical tests.
Supplementary Data Fig. S5 from ATM Paradoxically Promotes Oncogenic Transformation via Transcriptional Reprogramming
Authors: Liu Xinjian , Hu Mengjie , Liu Pei , Jiao Meng , Zhou Min , Lee Andrew K. , Li Fang , Li Chuan-Yuan
Published: April 2023

ATAC-seq analysis of chromatin accessibility in control and ATM knockout cells before and after MPOR oncogenic cocktail transduction.
Supplementary Data from RNA-Binding Protein ZFP36L1 Suppresses Hypoxia and Cell-Cycle Signaling
Authors: Loh Xin-Yi , Sun Qiao-Yang , Ding Ling-Wen , Mayakonda Anand , Venkatachalam Nachiyappan , Yeo Mei-Shi , Silva Tiago C. , Xiao Jin-Fen , Doan Ngan B. , Said Jonathan W. , Ran Xue-Bin , Zhou Si-Qin , Dakle Pushkar , Shyamsunder Pavithra , Koh Angele Pei-Fern , Huang Ruby Yun-Ju , Berman Benjamin P. , Tan Soo-Yong , Yang Henry , Lin De-Chen , Koeffler H. Phillip
Published: April 2023

ZFP36L1 is significantly downregulated and methylated in breast and bladder cancer, and inhibits cell cycle progression and hypoxia/HIF1A signaling.
Figure S6 from ATM Paradoxically Promotes Oncogenic Transformation via Transcriptional Reprogramming
Authors: Liu Xinjian , Hu Mengjie , Liu Pei , Jiao Meng , Zhou Min , Lee Andrew K. , Li Fang , Li Chuan-Yuan
Published: April 2023

Additional data on the key roles of KAP1 phosphorylation in MPOR-induced transformation of fibroblasts.
Figure S3 from ATM Paradoxically Promotes Oncogenic Transformation via Transcriptional Reprogramming
Authors: Liu Xinjian , Hu Mengjie , Liu Pei , Jiao Meng , Zhou Min , Lee Andrew K. , Li Fang , Li Chuan-Yuan
Published: April 2023

Additional gene expression profiling analysis of MPOR-induced transformation.
Figure S5 from LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance
Authors: Roberts Melyssa S. , Sahni Jennifer M. , Schrock Morgan S. , Piemonte Katrina M. , Weber-Bonk Kristen L. , Seachrist Darcie D. , Avril Stefanie , Anstine Lindsey J. , Singh Salendra , Sizemore Steven T. , Varadan Vinay , Summers Matthew K. , Keri Ruth A.
Published: April 2023

NEK2 silencing causes mitotic progression errors and increases taxane sensitivity.
Supplementary Dataset S3 from Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis
Authors: Singh Mohini , Venugopal Chitra , Tokar Tomas , McFarlane Nicole , Subapanditha Minomi K. , Qazi Maleeha , Bakhshinyan David , Vora Parvez , Murty Naresh K. , Jurisica Igor , Singh Sheila K.
Published: April 2023

GSEA of dysregulated BMIT genes within KEGG gene sets
Supplementary Data from Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells
Authors: Gomez Karina E. , Wu FangLong , Keysar Stephen B. , Morton J. Jason , Miller Bettina , Chimed Tugs-Saikhan , Le Phuong N. , Nieto Cera , Chowdhury Farshad N. , Tyagi Anit , Lyons Traci R. , Young Christian D. , Zhou Hongmei , Somerset Hilary L. , Wang Xiao-Jing , Jimeno Antonio
Published: April 2023

Supplemental methods, figures, and table.
Supplementary Data from Soft Microenvironments Induce Chemoresistance by Increasing Autophagy Downstream of Integrin-Linked Kinase
Authors: Anlaş Alişya A. , Nelson Celeste M.
Published: April 2023

Supplementary Figures 1-5. Figure S1. Substratum stiffness regulates proliferation and apoptosis in ZR-75-1 human breast cancer cells. Figure S2. Substratum stiffness regulates response to tamoxifen in MCF7 human breast cancer cells. Figure S3. Substratum stiffness regulates autophagy and response to tamoxifen in ZR-75-1 human breast cancer cells. Figure S4. The response of MCF7 cells to 5FU is regulated by substratum stiffness. Figure S5. Blocking autophagy pharmacologically renders MCF7 cells sensitive to 5FU.
Figure S2 from Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma
Authors: Qazi Maleeha A. , Vora Parvez , Venugopal Chitra , Adams Jarrett , Singh Mohini , Hu Amy , Gorelik Maryna , Subapanditha Minomi K. , Savage Neil , Yang Jiahe , Chokshi Chirayu , London Max , Gont Alexander , Bobrowski David , Grinshtein Natalie , Brown Kevin R. , Murty Naresh K. , Nilvebrant Johan , Kaplan David , Moffat Jason , Sidhu Sachdev , Singh Sheila K.
Published: April 2023

Characterization of EphA2+/EphA3+ sorted cell population overtime for changes in EphA2 and EphA3 surface expression.
Table S1 from A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Authors: Harrison Emily B. , Porrello Alessandro , Bowman Brittany M. , Belanger Adam R. , Yacovone Gabriella , Azam Salma H. , Windham Ian A. , Ghosh Subrata K. , Wang Menglin , Mckenzie Nicholas , Waugh Trent A. , Van Swearingen Amanda E.D. , Cohen Stephanie M. , Allen Devon G. , Goodwin Tyler J. , Mascenik Teresa , Bear James E. , Cohen Sarah , Randell Scott H. , Massion Pierre P. , Major Michael B. , Huang Leaf , Pecot Chad V.
Published: April 2023

Sequences of shRs and RT-qPCR primers.
Supplemental Table ST1 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
Authors: Gartrell-Corrado Robyn D. , Chen Andrew X. , Rizk Emanuelle M. , Marks Douglas K. , Bogardus Margaret H. , Hart Thomas D. , Silverman Andrew M. , Bayan Claire-Audrey Y. , Finkel Grace G. , Barker Luke W. , Komatsubara Kimberly M. , Carvajal Richard D. , Horst Basil A. , Chang Rui , Monod Anthea , Rabadan Raul , Saenger Yvonne M.
Published: April 2023

Patient characteristics of the Macrophage Survey sub-cohort.
Supplementary Figure S3 from Blocking Angiopoietin-2 Promotes Vascular Damage and Growth Inhibition in Mouse Tumors Treated with Small Doses of Radiation
Authors: Kallio Pauliina , Jokinen Elina , Högström Jenny , Das Suvendu , Heino Sarika , Lähde Marianne , Brodkin Jefim , Korhonen Emilia A. , Alitalo Kari
Published: April 2023

Supplementary Figure S3
Supplemental Figure S2 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
Authors: Gartrell-Corrado Robyn D. , Chen Andrew X. , Rizk Emanuelle M. , Marks Douglas K. , Bogardus Margaret H. , Hart Thomas D. , Silverman Andrew M. , Bayan Claire-Audrey Y. , Finkel Grace G. , Barker Luke W. , Komatsubara Kimberly M. , Carvajal Richard D. , Horst Basil A. , Chang Rui , Monod Anthea , Rabadan Raul , Saenger Yvonne M.
Published: April 2023

Cell clustering relates to gene expression. Spearman correlation of PCF AUC values from the tumor-CTL and tumor-macrophage HLA-DR+ interactions, compared with gene expression values. Statistical analysis performed using Fisher transformation with Bonferroni correction.
Supplementary Figures from FTO-Dependent N6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling
Authors: Huang Hao , Wang Yinu , Kandpal Manoj , Zhao Guangyuan , Cardenas Horacio , Ji Yanrong , Chaparala Anusha , Tanner Edward J. , Chen Jianjun , Davuluri Ramana V. , Matei Daniela
Published: April 2023

Additional experimental results supporting the main figures are included. Figure S1. Expression of key RNA methylation regulators in OC; Figure S2. Flow cytometry analysis for ALDH and CD133 in single cell suspensions derived from human ovarian tumors; Figure S3. FTO overexpression in OC cells; Figure S4. FTO overexpression decreases spheroid formation ability of OC cells dissociated from xenografts; Figure S5. m6A activity and tumor initiation capacity; Figure S6. Gene sets enriched in FTO vs. control OC cells; Figure S7. Expression of PDE4B and PDE1C in FTO overexpressed OC cells; Figure S8. The Genome Browser visualizes the predicted motif binding sites for proteins (IGF2BP2 and IGF2BP3) on the input sequence; Figure S9. Effects of phosphodiesterase inhibitors on stemness features are dependent on FTO; Figure S10. Quality control for RNA-seq; Figure S11. Quality control for MeRIP-seq
Figure S5 from Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
Authors: Voli Florida , Valli Emanuele , Lerra Luigi , Kimpton Kathleen , Saletta Federica , Giorgi Federico M. , Mercatelli Daniele , Rouaen Jourdin R.C. , Shen Sylvie , Murray Jayne E. , Ahmed-Cox Aria , Cirillo Giuseppe , Mayoh Chelsea , Beavis Paul A. , Haber Michelle , Trapani Joseph A. , Kavallaris Maria , Vittorio Orazio
Published: April 2023

DC increases tumor-infiltrating immune cells in Th-MYCN mice
Supplementary Figure 3 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
Authors: Yard Brian D. , Gopal Priyanka , Bannik Kristina , Siemeister Gerhard , Hagemann Urs B. , Abazeed Mohamed E.
Published: April 2023

Incubation time does not impact alpha-particle irradiation sensitivity on the basis of cellular doubling time.
Table. S1 from Hes1 Is Essential in Proliferating Ductal Cell–Mediated Development of Intrahepatic Cholangiocarcinoma
Authors: Matsumori Tomoaki , Kodama Yuzo , Takai Atsushi , Shiokawa Masahiro , Nishikawa Yoshihiro , Matsumoto Tomonori , Takeda Haruhiko , Marui Saiko , Okada Hirokazu , Hirano Tomonori , Kuwada Takeshi , Sogabe Yuko , Kakiuchi Nobuyuki , Tomono Teruko , Mima Atsushi , Morita Toshihiro , Ueda Tatsuki , Tsuda Motoyuki , Yamauchi Yuki , Kuriyama Katsutoshi , Sakuma Yojiro , Ota Yuji , Maruno Takahisa , Uza Norimitsu , Marusawa Hiroyuki , Kageyama Ryoichiro , Chiba Tsutomu , Seno Hiroshi
Published: April 2023

Primer sequences used for real-time PCR.
Fig. S5 from Hes1 Is Essential in Proliferating Ductal Cell–Mediated Development of Intrahepatic Cholangiocarcinoma
Authors: Matsumori Tomoaki , Kodama Yuzo , Takai Atsushi , Shiokawa Masahiro , Nishikawa Yoshihiro , Matsumoto Tomonori , Takeda Haruhiko , Marui Saiko , Okada Hirokazu , Hirano Tomonori , Kuwada Takeshi , Sogabe Yuko , Kakiuchi Nobuyuki , Tomono Teruko , Mima Atsushi , Morita Toshihiro , Ueda Tatsuki , Tsuda Motoyuki , Yamauchi Yuki , Kuriyama Katsutoshi , Sakuma Yojiro , Ota Yuji , Maruno Takahisa , Uza Norimitsu , Marusawa Hiroyuki , Kageyama Ryoichiro , Chiba Tsutomu , Seno Hiroshi
Published: April 2023

Histological analysis of ICC and the incidence of HCC developed in AlbcreKP; RosaNotchOE and AlbcreKP; RosaNotchOE; Hes1flox/flox mice at 8 weeks of age.
Fig. S2 from Hes1 Is Essential in Proliferating Ductal Cell–Mediated Development of Intrahepatic Cholangiocarcinoma
Authors: Matsumori Tomoaki , Kodama Yuzo , Takai Atsushi , Shiokawa Masahiro , Nishikawa Yoshihiro , Matsumoto Tomonori , Takeda Haruhiko , Marui Saiko , Okada Hirokazu , Hirano Tomonori , Kuwada Takeshi , Sogabe Yuko , Kakiuchi Nobuyuki , Tomono Teruko , Mima Atsushi , Morita Toshihiro , Ueda Tatsuki , Tsuda Motoyuki , Yamauchi Yuki , Kuriyama Katsutoshi , Sakuma Yojiro , Ota Yuji , Maruno Takahisa , Uza Norimitsu , Marusawa Hiroyuki , Kageyama Ryoichiro , Chiba Tsutomu , Seno Hiroshi
Published: April 2023

Analyzes of AlbcreK; Hes1WT/WT, AlbcreK; Hes1flox/flox, AlbcreKP; Hes1WT/WT, and AlbcreKP; Hes1flox/flox mice.
Supplementary Figures and Table with legends from Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS–Dependent Pancreatic Ductal Adenocarcinoma
Authors: Mottini Carla , Tomihara Hideo , Carrella Diego , Lamolinara Alessia , Iezzi Manuela , Huang Justin K. , Amoreo Carla A. , Buglioni Simonetta , Manni Isabella , Robinson Frederick S. , Minelli Rosalba , Kang Ya'an , Fleming Jason B. , Kim Michael P. , Bristow Christopher A. , Trisciuoglio Daniela , Iuliano Antonella , Del Bufalo Donatella , Di Bernardo Diego , Melisi Davide , Draetta Giulio F. , Ciliberto Gennaro , Carugo Alessandro , Cardone Luca
Published: April 2023

Supplementary Figures and Table with legends
Supplementary Tables from The Amino-Terminal Oligomerization Domain of Angiopoietin-2 Affects Vascular Remodeling, Mammary Gland Tumor Growth, and Lung Metastasis in Mice
Authors: Kapiainen Emmi , Kihlström Minna K. , Pietilä Riikka , Kaakinen Mika , Ronkainen Veli-Pekka , Tu Hongmin , Heikkinen Anne , Devarajan Raman , Miinalainen Ilkka , Laitakari Anna , Ansarizadeh Mohammadhassan , Zhang Qin , Wei Gong-Hong , Ruddock Lloyd , Pihlajaniemi Taina , Elamaa Harri , Eklund Lauri
Published: April 2023

Supplementary Tables I-III
Supplemental Figure 4 from Palmitoylated Proteins on AML-Derived Extracellular Vesicles Promote Myeloid-Derived Suppressor Cell Differentiation via TLR2/Akt/mTOR Signaling
Authors: Tohumeken Sehmus , Baur Rebecca , Böttcher Martin , Stoll Andrej , Loschinski Romy , Panagiotidis Konstantinos , Braun Martina , Saul Domenica , Völkl Simon , Baur Andreas S. , Bruns Heiko , Mackensen Andreas , Jitschin Regina , Mougiakakos Dimitrios
Published: April 2023

Changes of mitochondrial (A) membrane potential, (B) ROS production, and (C) mass in monocytes upon AML-EV uptake.
Supplemental Figure 3 from Palmitoylated Proteins on AML-Derived Extracellular Vesicles Promote Myeloid-Derived Suppressor Cell Differentiation via TLR2/Akt/mTOR Signaling
Authors: Tohumeken Sehmus , Baur Rebecca , Böttcher Martin , Stoll Andrej , Loschinski Romy , Panagiotidis Konstantinos , Braun Martina , Saul Domenica , Völkl Simon , Baur Andreas S. , Bruns Heiko , Mackensen Andreas , Jitschin Regina , Mougiakakos Dimitrios
Published: April 2023

(A) Induction of MDSCs by AML-EVs released by chemotherapy-pretreated AML celllines, (B) Phagocytotic activity of monocytes upon AML-EV uptake, (C) Induction of MDSCs by AML-EVs isolated by gradient ultracentrifugation, (D) Induction of pCREB by AML-EVs.
Figure S6 from Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells
Authors: Alvarez-Trotta Annamil , Guerrant William , Astudillo Luisana , Lahiry Mohini , Diluvio Giulia , Shersher Elena , Kaneku Hugo , Robbins David J. , Orton Darren , Capobianco Anthony J.
Published: April 2023

IHC of EAC47 PDX treated with NADI-351 for 30 days
Table S4 from Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes
Authors: Apostolidi Maria , Vathiotis Ioannis A. , Muthusamy Viswanathan , Gaule Patricia , Gassaway Brandon M. , Rimm David L. , Rinehart Jesse
Published: April 2023

AQUA analysis of YTMA128 and YTMA341 breast cancer patient cohorts.
Figure S6 from Mesothelin-Specific CAR T Cells Target Ovarian Cancer
Authors: Schoutrop Esther , El-Serafi Ibrahim , Poiret Thomas , Zhao Ying , Gultekin Okan , He Rui , Moyano-Galceran Lidia , Carlson Joseph W. , Lehti Kaisa , Hassan Moustapha , Magalhaes Isabelle , Mattsson Jonas
Published: April 2023

Figure S6
Figure S4 from Mesothelin-Specific CAR T Cells Target Ovarian Cancer
Authors: Schoutrop Esther , El-Serafi Ibrahim , Poiret Thomas , Zhao Ying , Gultekin Okan , He Rui , Moyano-Galceran Lidia , Carlson Joseph W. , Lehti Kaisa , Hassan Moustapha , Magalhaes Isabelle , Mattsson Jonas
Published: April 2023

Figure S4
Figure S3 from Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance
Authors: Zhang Xu , Maity Tapan K. , Ross Karen E. , Qi Yue , Cultraro Constance M. , Bahta Meriam , Pitts Stephanie , Keswani Meghana , Gao Shaojian , Nguyen Khoa Dang P. , Cowart Julie , Kirkali Fatos , Wu Cathy , Guha Udayan
Published: April 2023

Supplementary Fig. S3
Supplementary Data from Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance
Authors: Ghildiyal Ruchi , Sawant Mithila , Renganathan Arun , Mahajan Kiran , Kim Eric H. , Luo Jingqin , Dang Ha X. , Maher Christopher A. , Feng Felix Y. , Mahajan Nupam P.
Published: April 2023

Supplementary Figures 1-10 and Tables 1-3
Figure S7 from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma
Authors: Krenz Bastian , Gebhardt-Wolf Anneli , Ade Carsten P. , Gaballa Abdallah , Roehrig Florian , Vendelova Emilia , Baluapuri Apoorva , Eilers Ursula , Gallant Peter , D'Artista Luana , Wiegering Armin , Gasteiger Georg , Rosenfeldt Mathias T. , Bauer Stefan , Zender Lars , Wolf Elmar , Eilers Martin
Published: April 2023

Role of MIZ1 in gene regulation.
Figure S3 from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma
Authors: Krenz Bastian , Gebhardt-Wolf Anneli , Ade Carsten P. , Gaballa Abdallah , Roehrig Florian , Vendelova Emilia , Baluapuri Apoorva , Eilers Ursula , Gallant Peter , D'Artista Luana , Wiegering Armin , Gasteiger Georg , Rosenfeldt Mathias T. , Bauer Stefan , Zender Lars , Wolf Elmar , Eilers Martin
Published: April 2023

Characterization of MYC depletion.
Supplementary Data from PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer
Authors: Yu Tian-Jian , Liu Ying-Ying , Li Xiao-Guang , Lian Bi , Lu Xun-Xi , Jin Xi , Shao Zhi-Ming , Hu Xin , Di Gen-Hong , Jiang Yi-Zhou
Published: April 2023

Figure S1-S13 and Table S1-S3
Supplementary File from Label-Free Deep Profiling of the Tumor Microenvironment
Authors: You Sixian , Chaney Eric J. , Tu Haohua , Sun Yi , Sinha Saurabh , Boppart Stephen A.
Published: April 2023

Supplementary file
Supplementary Data from miR-31 Displays Subtype Specificity in Lung Cancer
Authors: Davenport Mackenzie L. , Echols John B. , Silva Austin D. , Anderson Joshua C. , Owens Philip , Yates Clayton , Wei Qing , Harada Shuko , Hurst Douglas R. , Edmonds Mick D.
Published: April 2023

Supplemental figures and legends
Supplementary Data from Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL
Authors: Goldberg Liat , Negi Vijay , Chung Yang Jo , Onozawa Masahiro , Zhu Yuelin J. , Walker Robert L. , Pierce Rachel , Patel Daxesh P. , Krausz Kristopher W. , Gonzalez Frank J. , Goodell Margaret A. , Rodriguez Benjamin A.T. , Meltzer Paul S. , Aplan Peter D.
Published: April 2023

Supplementary Figures and tables.
Supplementary Figure from PKM2 Is Essential for Bladder Cancer Growth and Maintenance
Authors: Xia Yong , Wang Xing , Liu Yan , Shapiro Ellen , Lepor Herbert , Tang Moon-Shong , Sun Tung-Tien , Wu Xue-Ru
Published: April 2023

Supplementary Figure from PKM2 Is Essential for Bladder Cancer Growth and Maintenance
Supplementary Data from Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia
Authors: Biran Anat , Yin Shanye , Kretzmer Helene , ten Hacken Elisa , Parvin Salma , Lucas Fabienne , Uduman Mohamed , Gutierrez Catherine , Dangle Nathan , Billington Leah , Regis Fara Faye , Rassenti Laura Z. , Mohammad Arman , Hoffmann Gabriela Brunsting , Stevenson Kristen , Zheng Mei , Witten Elizabeth , Fernandes Stacey M. , Tausch Eugen , Sun Clare , Stilgenbauer Stephan , Brown Jennifer R. , Kipps Thomas J. , Aster John C. , Gnirke Andreas , Neuberg Donna S. , Letai Anthony , Wang Lili , Carrasco Ruben D. , Meissner Alexander , Wu Catherine J.
Published: April 2023

Supplementary Tables contain Supplementary Tables S1-17
Supplementary Figures from Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth
Authors: Cook Danielle R. , Kang Melissa , Martin Timothy D. , Galanko Joseph A. , Loeza Gabriela H. , Trembath Dimitri G. , Justilien Verline , Pickering Karen A. , Vincent David F. , Jarosch Armin , Jurmeister Philipp , Waters Andrew M. , Hibshman Priya S. , Campbell Andrew D. , Ford Catriona A. , Keku Temitope O. , Yeh Jen Jen , Lee Michael S. , Cox Adrienne D. , Fields Alan P. , Sandler Robert S. , Sansom Owen J. , Sers Christine , Schaefer Antje , Der Channing J.
Published: April 2023

Supplementary Figures S1-S4
Supplementary Figure S4 from Hepatitis B–Induced IL8 Promotes Hepatocellular Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation
Authors: Zhang Changlu , Gao Yanan , Du Chengzhi , Markowitz Geoffrey J. , Fu Jing , Zhang Zhenxing , Liu Chunliang , Qin Wenhao , Wang Hongyang , Wang Fan , Yang Pengyuan
Published: April 2023

Supplementary Figure S4 shows IL-8-CXCR1 axis has no effect on immune cell infiltration in lung and spleen
Table S2 from ZIP9 Is a Druggable Determinant of Sex Differences in Melanoma
Authors: Aguirre-Portolés Cristina , Payne Riley , Trautz Aspen , Foskett J. Kevin , Natale Christopher A. , Seykora John T. , Ridky Todd W.
Published: April 2023

Features and statistical significance of the survival analyses extracted from OSskm
Supplementary Figure 8 from ZIP9 Is a Druggable Determinant of Sex Differences in Melanoma
Authors: Aguirre-Portolés Cristina , Payne Riley , Trautz Aspen , Foskett J. Kevin , Natale Christopher A. , Seykora John T. , Ridky Todd W.
Published: April 2023

Expression of classical and non-classical sex steroid receptors in primary human melanocytes. Testosterone promotes proliferation of genetically diverse cell lines.
Supplementary Table 1 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma
Authors: Maze Emmanuel A. , Agit Bora , Reeves Shona , Hilton David A. , Parkinson David B. , Laraba Liyam , Ercolano Emanuela , Kurian Kathreena M. , Hanemann C. Oliver , Belshaw Robert D. , Ammoun Sylwia
Published: April 2023

Supplementary Table 1
Table 1 and legend
Supplementary Figures from STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer
Authors: Kutschat Ana P. , Hamdan Feda H. , Wang Xin , Wixom Alexander Q. , Najafova Zeynab , Gibhardt Christine S. , Kopp Waltraut , Gaedcke Jochen , Ströbel Philipp , Ellenrieder Volker , Bogeski Ivan , Hessmann Elisabeth , Johnsen Steven A.
Published: April 2023

Supplementary Figures S1-S10
Supplementary Data from Oncostatin M Receptor–Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth
Authors: Geethadevi Anjali , Nair Ajay , Parashar Deepak , Ku Zhiqiang , Xiong Wei , Deng Hui , Li Yongsheng , George Jasmine , McAllister Donna M. , Sun Yunguang , Kadamberi Ishaque P. , Gupta Prachi , Dwinell Michael B. , Bradley William H. , Rader Janet S. , Rui Hallgeir , Schwabe Robert F. , Zhang Ningyan , Pradeep Sunila , An Zhiqiang , Chaluvally-Raghavan Pradeep
Published: April 2023

Supplementary Material-1. Heatmap shows all the known ligand-receptor interactions between different cell types identified by CellPhoneDB in the OvD5-SS2 dataset.
Supplementary Figure from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures
Authors: Yu Xiaoqing , Cen Ling , Chen Y. Ann , Markowitz Joseph , Shaw Timothy I. , Tsai Kenneth Y. , Conejo-Garcia Jose R. , Wang Xuefeng
Published: April 2023

Supplementary Figure from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures
Supplementary Data from Caspase-3–Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma
Authors: Mok Etienne Ho Kit , Leung Carmen Oi Ning , Zhou Lei , Lei Martina Mang Leng , Leung Hoi Wing , Tong Man , Wong Tin Lok , Lau Eunice Yuen Ting , Ng Irene Oi Lin , Ding Jin , Yun Jing Ping , Yu Jun , Zhu Hui Lian , Lin Chi Ho , Lindholm Dan , Leung Kit Sum , Cybulski Jonathan D. , Baker David M. , Ma Stephanie , Lee Terence Kin Wah
Published: April 2023

Supplementary Data from Caspase-3–Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma
Supplementary Data from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase METTL3
Authors: Liao Long , He Yan , Li Shu-Jun , Zhang Guo-Geng , Yu Wei , Yang Jing , Huang Zi-Jia , Zheng Can-Can , He Qing-Yu , Li Yan , Li Bin
Published: April 2023

Supplementary Data from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase METTL3
Table S4 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Authors: Liu Jianglan , Rebecca Vito W. , Kossenkov Andrew V. , Connelly Thomas , Liu Qin , Gutierrez Alexis , Xiao Min , Li Ling , Zhang Gao , Samarkina Anastasia , Zayasbazan Delaine , Zhang Jie , Cheng Chaoran , Wei Zhi , Alicea Gretchen M. , Fukunaga-Kalabis Mizuho , Krepler Clemens , Aza-Blanc Pedro , Yang Chih-Cheng , Delvadia Bela , Tong Cynthia , Huang Ye , Delvadia Maya , Morias Alice S. , Sproesser Katrin , Brafford Patricia , Wang Joshua X. , Beqiri Marilda , Somasundaram Rajasekharan , Vultur Adina , Hristova Denitsa M. , Wu Lawrence W. , Lu Yiling , Mills Gordon B. , Xu Wei , Karakousis Giorgos C. , Xu Xiaowei , Schuchter Lynn M. , Mitchell Tara C. , Amaravadi Ravi K. , Kwong Lawrence N. , Frederick Dennie T. , Boland Genevieve M. , Salvino Joseph M. , Speicher David W. , Flaherty Keith T. , Ronai Ze'ev A. , Herlyn Meenhard
Published: April 2023

Supplementary Table
Data from Targeting BRCA1 Localization to Augment Breast Tumor Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
Authors: Yang Eddy S. , Nowsheen Somaira , Rahman Mohammad A. , Cook Rebecca S. , Xia Fen
Published: April 2023

Abstract
PARP inhibitors have gained recent attention due to their highly selective killing of BRCA1/2-mutated and DNA double-strand break (DSB) repair–deficient tumors. Unfortunately, the majority of sporadic breast cancers carry wild-type BRCA1/2 and are proficient in DSB repair. We and others have shown that BRCA1 is a nuclear/cytoplasm shuttling protein that is transiently exported from the nucleus to the cytosol upon various stimuli. Thus, we hypothesized that depletion of nuclear BRCA1 would compromise DSB repair and subsequently render sporadic tumors susceptible to PARP inhibition. Indeed, in human sporadic breast cancer cells with functional BRCA1 and proficient DSB repair, a transient nuclear depletion of BRCA1 and subsequent homologous recombination repair deficit was induced with either truncated BRCA1 or irradiation. This rendered these human sporadic breast cancer cells susceptible to PARP inhibition. These observations were confirmed genetically using mislocated BRCA1 mutants as well as in vivo in mice bearing breast tumor xenografts. These data support the potential strategy of targeting BRCA1 location to convert BRCA1-proficient sporadic tumors to be susceptible to the synthetic lethal combination with PARP inhibitors. Cancer Res; 72(21); 5547–55. ©2012 AACR.
Data from VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity–Induced Tumor Regression
Authors: Doloff Joshua C. , Waxman David J.
Published: April 2023

Abstract
In metronomic chemotherapy, frequent drug administration at lower than maximally tolerated doses can improve activity while reducing the dose-limiting toxicity of conventional dosing schedules. Although the antitumor activity produced by metronomic chemotherapy is attributed widely to antiangiogenesis, the significance of this mechanism remains somewhat unclear. In this study, we show that a 6-day repeating metronomic schedule of cyclophosphamide administration activates a potent antitumor immune response associated with brain tumor recruitment of natural killer (NK) cells, macrophages, and dendritic cells that leads to marked tumor regression. Tumor regression was blocked in nonobese diabetic/severe combined immunodeficient (NOD/SCID-γ) mice, which are deficient or dysfunctional in all these immune cell types. Furthermore, regression was blunted by NK cell depletion in immunocompetent syngeneic mice or in perforin-deficient mice, which are compromised for NK, NKT, and T-cell cytolytic functions. Unexpectedly, we found that VEGF receptor inhibitors blocked both innate immune cell recruitment and the associated tumor regression response. Cyclophosphamide administered at a maximum tolerated dose activated a transient, weak innate immune response, arguing that persistent drug-induced cytotoxic damage or associated cytokine and chemokine responses are required for effective innate immunity–based tumor regression. Together, our results reveal an innate immunity–based mechanism of tumor regression that can be activated by a traditional cytotoxic chemotherapy administered on a metronomic schedule. These findings suggest the need to carefully evaluate the clinical effects of combination chemotherapies that incorporate antiangiogenesis drugs targeting VEGF receptor. Cancer Res; 72(5); 1103–15. ©2012 AACR.
Data from Colorectal Cancer Risk Associated with Hormone Use Varies by Expression of Estrogen Receptor-β
Authors: Rudolph Anja , Toth Csaba , Hoffmeister Michael , Roth Wilfried , Herpel Esther , Schirmacher Peter , Brenner Hermann , Chang-Claude Jenny
Published: April 2023

Abstract
The risk of colorectal cancer is reduced among users of oral contraceptives or menopausal hormone therapy, but associations with reproductive characteristics that are markers of a woman's endogenous hormone milieu have not been consistently observed. To help understand possible mechanisms through which exogenous and endogenous hormonal exposures are involved in colorectal cancer, we assessed the risk of these malignancies according to tumor expression of estrogen receptor-β (ESR2). In a population-based study of postmenopausal women (503 cases and 721 controls matched for sex and age), immunohistochemical expression of ESR2 was determined in 445 cases of incident colorectal cancer. Unconditional logistic regression was used in case–case analyses to assess heterogeneity between risk associations according to ESR2 status and in case–control analyses to estimate associations separately for ESR2-negative and ESR2-positive tumors. For ESR2-positive tumors but not ESR2-negative tumors, colorectal cancer risk significantly decreased with duration of oral contraceptive use [per five-year increments OR ESR2-positive, 0.87, 95% confidence interval (CI), 0.77–0.99; OR ESR2-negative, 1.02, 95% CI, 0.91–1.15; Pheterogeneity = 0.07] and with duration of menopausal hormone therapy use (per five-year increments OR ESR2-positive, 0.84, 95% CI, 0.74–0.95; OR ESR2-negative, 0.94, 95% CI 0.84–1.05; Pheterogeneity = 0.06). Significant heterogeneity according to ESR2 expression was found for the association with current use of menopausal hormone therapy (<0.5 years ago; Pheterogeneity = 0.023) but not for associations with reproductive factors. In conclusion, our results suggest that hormone use decreases risk for ESR2-positive but not ESR2-negative colorectal cancer. Cancer Res; 73(11); 3306–15. ©2013 AACR.
Data from Dysregulation of Ezrin Phosphorylation Prevents Metastasis and Alters Cellular Metabolism in Osteosarcoma
Authors: Ren Ling , Hong Sung-Hyeok , Chen Qing-Rong , Briggs Joseph , Cassavaugh Jessica , Srinivasan Satish , Lizardo Michael M. , Mendoza Arnulfo , Xia Ashley Y. , Avadhani Narayan , Khan Javed , Khanna Chand
Published: April 2023

Abstract
Ezrin links the plasma membrane to the actin cytoskeleton where it plays a pivotal role in the metastatic progression of several human cancers; however, the precise mechanistic basis for its role remains unknown. Here, we define transitions between active (phosphorylated open) and inactive (dephosphorylated closed) forms of Ezrin that occur during metastatic progression in osteosarcoma. In our evaluation of these conformations we expressed C-terminal mutant forms of Ezrin that are open (phosphomimetic T567D) or closed (phosphodeficient T567A) and compared their biologic characteristics to full-length wild-type Ezrin in osteosarcoma cells. Unexpectedly, cells expressing open, active Ezrin could form neither primary orthotopic tumors nor lung metastases. In contrast, cells expressing closed, inactive Ezrin were also deficient in metastasis but were unaffected in their capacity for primary tumor growth. By imaging single metastatic cells in the lung, we found that cells expressing either open or closed Ezrin displayed increased levels of apoptosis early after their arrival in the lung. Gene expression analysis suggested dysregulation of genes that are functionally linked to carbohydrate and amino acid metabolism. In particular, cells expressing closed, inactive Ezrin exhibited reduced lactate production and basal or ATP-dependent oxygen consumption. Collectively, our results suggest that dynamic regulation of Ezrin phosphorylation at amino acid T567 that controls structural transitions of this protein plays a pivotal role in tumor progression and metastasis, possibly in part by altering cellular metabolism. Cancer Res; 72(4); 1001–12. ©2011 AACR.
Data from VEGF-A Expression Correlates with TP53 Mutations in Non–Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy
Authors: Schwaederlé Maria , Lazar Vladimir , Validire Pierre , Hansson Johan , Lacroix Ludovic , Soria Jean-Charles , Pawitan Yudi , Kurzrock Razelle
Published: April 2023

Abstract
Bevacizumab is one of the most widely used antiangiogenic drugs in oncology, but the overall beneficial effects of this VEGF-A targeting agent are relatively modest, in part due to the lack of a biomarker to select patients most likely to respond favorably. Several molecular aberrations in cancer influence angiogenesis, including mutations in the tumor suppressor gene TP53, which occur frequently in many human malignancies. In this study, we present a multiple regression analysis of transcriptomic data in 123 patients with non–small cell lung cancer (NSCLC) showing that TP53 mutations are associated with higher VEGF-A expression (P = 0.006). This association was interesting given a recent retrospective study showing longer progression-free survival in patients with diverse tumors who receive bevacizumab, if tumors harbor mutant TP53 instead of wild-type TP53. Thus, our current findings linking TP53 mutation with VEGF-A upregulation offered a mechanistic explanation for why patients exhibit improved outcomes after bevacizumab treatment when their tumors harbor mutant TP53 versus wild-type TP53. Overall, this work warrants further evaluation of TP53 as a ready biomarker to predict bevacizumab response in NSCLC and possibly other tumor types. Cancer Res; 75(7); 1187–90. ©2015 AACR.
Data from Immuno-PET Imaging of Engineered Human T Cells in Tumors
Authors: Mall Sabine , Yusufi Nahid , Wagner Ricarda , Klar Richard , Bianchi Henrique , Steiger Katja , Straub Melanie , Audehm Stefan , Laitinen Iina , Aichler Michaela , Peschel Christian , Ziegler Sibylle , Mustafa Mona , Schwaiger Markus , D'Alessandria Calogero , Krackhardt Angela M.
Published: April 2023

Abstract
Sensitive in vivo imaging technologies applicable to the clinical setting are still lacking for adoptive T-cell–based immunotherapies, an important gap to fill if mechanisms of tumor rejection or escape are to be understood. Here, we propose a highly sensitive imaging technology to track human TCR-transgenic T cells in vivo by directly targeting the murinized constant TCR beta domain (TCRmu) with a zirconium-89 (89Zr)-labeled anti–TCRmu-F(ab')2 fragment. Binding of the labeled or unlabeled F(ab')2 fragment did not impair functionality of transgenic T cells in vitro and in vivo. Using a murine xenograft model of human myeloid sarcoma, we monitored by Immuno-PET imaging human central memory T cells (TCM), which were transgenic for a myeloid peroxidase (MPO)–specific TCR. Diverse T-cell distribution patterns were detected by PET/CT imaging, depending on the tumor size and rejection phase. Results were confirmed by IHC and semiquantitative evaluation of T-cell infiltration within the tumor corresponding to the PET/CT images. Overall, these findings offer a preclinical proof of concept for an imaging approach that is readily tractable for clinical translation. Cancer Res; 76(14); 4113–23. ©2016 AACR.
Data from Enhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells In Vivo
Authors: Rao Shreyas S. , Bushnell Grace G. , Azarin Samira M. , Spicer Graham , Aguado Brian A. , Stoehr Jenna R. , Jiang Eric J. , Backman Vadim , Shea Lonnie D. , Jeruss Jacqueline S.
Published: April 2023

Abstract
The onset of distant organ metastasis from primary breast cancer marks the transition to a stage IV diagnosis. Standard imaging modalities often detect distant metastasis when the burden of disease is high, underscoring the need for improved methods of detection to allow for interventions that would impede disease progression. Here, microporous poly(ϵ-caprolactone) scaffolds were developed that capture early metastatic cells and thus serve as a sentinel for early detection. These scaffolds were used to characterize the dynamic immune response to the implant spanning the acute and chronic foreign body response. The immune cell composition had stabilized at the scaffold after approximately 1 month and changed dramatically within days to weeks after tumor inoculation, with CD11b+Gr1hiLy6C− cells having the greatest increase in abundance. Implanted scaffolds recruited metastatic cancer cells that were inoculated into the mammary fat pad in vivo, which also significantly reduced tumor burden in the liver and brain. Additionally, cancer cells could be detected using a label-free imaging modality termed inverse spectroscopic optical coherence tomography, and we tested the hypothesis that subsequent removal of the primary tumor after early detection would enhance survival. Surgical removal of the primary tumor following cancer cell detection in the scaffold significantly improved disease-specific survival. The enhanced disease-specific survival was associated with a systemic reduction in the CD11b+Gr1hiLy6C− cells as a consequence of the implant, which was further supported by Gr-1 depletion studies. Implementation of the scaffold may provide diagnostic and therapeutic options for cancer patients in both the high-risk and adjuvant treatment settings. Cancer Res; 76(18); 5209–18. ©2016 AACR.